ACRV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Acrivon Therapeutics Inc (ACRV) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock lacks clear positive momentum, has weak financial performance, and no significant catalysts or trading signals to justify immediate action. Holding or waiting for further developments is recommended.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 47.665, suggesting no clear overbought or oversold conditions. Moving averages are converging, showing no strong trend. The stock is trading below its pivot level (1.623), with key support at 1.457 and resistance at 1.79.
Analyst Piper Sandler raised the price target to $8 from $6, citing positive Phase II data for ACR-368 and plans to submit an IND for ACR-6840 in Q4 2026.
The stock has seen a consistent decline in price (-5.33% regular market change, -4.14% pre-market change, -0.83% post-market change). Financial performance is weak, with no revenue growth, a significant net income drop (-18.75% YoY), and worsening EPS (-20.34% YoY).
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$18.23M (-18.75% YoY), and a drop in EPS to -0.47 (-20.34% YoY). Gross margin remained at 0%.
Piper Sandler maintains an Overweight rating and raised the price target to $8 from $6, citing positive Phase II data and future pipeline developments.
